ARTICLE | Company News
Warp Drive Bio Inc. (Cambridge, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) partnered on Monday to discover and develop antibiotics using Warp Drive's Genome Mining Platform, which uses a database of bacterial DNA sequences and search algorithms to identify and extract genes that can be used to produce natural products (see BioCentury, Jan. 18, 2016).
Warp Drive is eligible to receive $87 million in upfront cash, option fees and preclinical milestones, plus $300 million in clinical, regulatory and sales milestones and tiered double-digit royalties. Roche may opt to develop and commercialize a predefined number of antibiotic classes, triggered by the selection of a candidate from a particular class...